Patents Assigned to CANCURE LIMITED
  • Patent number: 10953045
    Abstract: Immune-potentiating compositions include cells exhibiting enhanced antigen-presenting functions. The compositions are generally useful in facilitating the stimulation of host immune cell responses, including selective and targeted immune cell responses, and are particularly useful in the treatment and/or prophylaxis of cancers, tumors and pathogenic infections.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: March 23, 2021
    Assignee: CANCURE LIMITED
    Inventor: Stephen Ralph
  • Patent number: RE47300
    Abstract: This invention relates to anti-cancer compounds and to methods for treating or preventing cancer. In one aspect the invention concerns mitochondrially delivered pro-oxidant anti-cancer compounds that generate reactive oxygen species and induce apoptosis of cancerous cells. The delivery moiety can be a lipophilic cation and the pro-oxidant moiety can be a pro-oxidant vitamin E analogue, such as ?-tocopheryl succinate, ?-tocopheryl maleate, ?-tocopheryl maleyl amide, or 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)-chroman-6-yloxyacetic acid (?-tocopheryloxyacetic acid).
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: March 19, 2019
    Assignee: CANCURE LIMITED
    Inventors: Stephen John Ralph, Jiri Neuzil